pharmaphorum

DECEMBER 6, 2022

Pfizer and partner BioNTech have launched a countersuit against Moderna in a patent despite centring on their mRNA-based vaccines for COVID-19. It also waived its rights to bring the lawsuit when it pledged not to sure other COVID-19 vaccine producers during the pandemic, according to Reuters.

Vaccines 97

Vaccines Immunity Immunization Drug Development 97

pharmaphorum

DECEMBER 8, 2021

A study by the African Health Research Institute (AHRI) has found that the less of immune protection was “extensive but incomplete,” meaning that some level of immunity was retained against the vaccine.

Vaccines 98

Vaccines Immunity Immunization Drug Development 98

pharmaphorum

MARCH 10, 2022

With a tight lens on late translational through to phase II clinical progress; the 2nd Chronic HBV Drug Development Summit is dedicated to advancing direct antiviral and immunotherapy pipelines in combination therapy paradigms. The post Welcome to the 2nd Chronic HBV Drug Development Summit appeared first on.

Drug Development 52

Drug Development Immunization Immunity Vaccines 52

pharmaphorum

MARCH 30, 2022

CureVac and GlaxoSmithKline’s first attempt to develop a COVID-19 vaccine was a salutary reminder of the pitfalls in drug development, as the mRNA shot crashed and burned in a clinical trial last year, but they aren’t giving up.

Vaccines 64

Vaccines Immunity Immunization Drug Development 64

pharmaphorum

JANUARY 6, 2023

The UK has formed an partnership with German biotech BioNTech to provide up to 10,000 patients with access to personalised cancer therapies, in another example of the country embracing the mRNA technologies that underpinned COVID-19 vaccines. It will also cover some infectious disease targets.

Vaccines 111

Vaccines Immunity Immunization Drug Development 111

pharmaphorum

NOVEMBER 23, 2021

Sanofi is the first pharma company to partner with Baidu on its LinearDesign AI platform, which has been developed specifically to optimise the sequence of mRNA-based vaccines and drugs. billion earlier this year. Specific financial terms have not been disclosed.

Vaccines 105

Vaccines Immunity Immunization Drug Development 105

Pharmaceutical Business Review

AUGUST 28, 2023

These candidates are being developed to offer better protection, extend the duration in preventing illness and transmission, as compared to the current vaccine technologies. The study will compare the relative efficacy of next-generation vaccines against approved vaccines to prevent symptomatic, PCR-confirmed SARS-CoV-2 infection.

Vaccines 52

Vaccines Clinical Pharmacology Immunization Immunity 52

Pharmaceutical Technology

FEBRUARY 1, 2023

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccines 64

Vaccines Drug Development Pharmaceutical Companies Pharmaceutical Companies 64

European Pharmaceutical Review

DECEMBER 22, 2022

The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category” The term ‘mRNA’ has become commonplace globally. The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category.

Immunity 116

Immunity Immunization Vaccines Hospitals 116

pharmaphorum

JANUARY 17, 2022

The drug, developed by Incyte and licenced to Lilly, is also used to treat rheumatoid arthritis. It prevents the overstimulation of the immune system and is said to improve survival and reduce the need for ventilation in covid-19 patients, with no observed increase in adverse effects.

Hospitals 116

Hospitals Diabetes Immunity Immunization 116

pharmaphorum

AUGUST 27, 2020

Regulatory pressures, lengthy drug development times, and the fact that drug prices have become politicised have raised risks and cut revenue projections, leading to the biotech sector falling out of fashion. Moreover, the range of companies benefiting from investor interest has not been limited to those developing a vaccine.

Vaccines 122

Vaccines Drug Pricing Compounding Immunity 122

pharmaphorum

JANUARY 18, 2022

Cancer Research UK’s Centre for Drug Development, working with the Ludwig Institute for Cancer Research and Vaccitech, has begun a phase I/IIa clinical trial of a new lung cancer vaccine. Vaccitech and the Ludwig Institute are providing the drug while the Centre manages the trial and provides funding.

Immunization 64

Immunization Immunity Vaccines Drug Development 64

pharmaphorum

NOVEMBER 2, 2020

With a collective sense of uncertainty, many are pinning their hopes on a vaccine and treatment, and sophisticated technology could help speed up the process of finding an effective medicine. This knowledge is critical in understanding how effective certain drugs might be in treating the virus. One example is Novartis.

Vaccines 132

Vaccines Drug Development Diabetes Immunity 132

pharmaphorum

AUGUST 23, 2022

With COVID-19 vaccines and therapeutics developed in rapid time, Ben Hargreaves investigates why this has not been the case with the creation of a treatment for Long COVID. Once the scale of the threat was understood, the pharmaceutical industry reacted with a rapidity and agility that allowed vaccines to be developed at a record rate.

Vaccines 134

Vaccines Immunity Immunization Drug Development 134

Pharmaceutical Technology

JUNE 10, 2023

Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. According to GlobalData, Phase I drugs for Pandemic Influenza does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here.

Vaccines 40

Vaccines Immunization Immunity Hospitals 40

Pharmaceutical Technology

JUNE 10, 2023

Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. According to GlobalData, Phase I drugs for Pandemic Influenza does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here.

Vaccines 40

Vaccines Immunization Immunity Hospitals 40

Pharmaceutical Technology

AUGUST 1, 2022

Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines.

Vaccines 93

Vaccines Pharmaceutical Companies Pharmaceutical Companies Chemotherapy 93

pharmaphorum

OCTOBER 12, 2022

“We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says. Del Bourgo highlights that genomic treatments work in a similar way to mRNA, which has been used in COVID-19 vaccines.

Drug Development 105

Drug Development Immunity Immunization Vaccines 105

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives.

Drug Development 52

Drug Development Immunity Immunization Hospitals 52

pharmaphorum

JANUARY 13, 2022

Other companies with active alpha-synuclein programmes include AstraZeneca and Takeda with antibody MEDI 1342 in phase 2 for Parkinson’s, AC Immune and its vaccine candidate ACI-7104, and small-molecular drug developers including Gain Therapeutics, MODAG, and Alterity Therapeutics.

Immunity 98

Immunity Immunization Vaccines Drug Development 98

pharmaphorum

NOVEMBER 4, 2020

The picture is hardly more promising for vaccines: the number of approaches, difficulty in finding patients in which to carry out pivotal trials, irrelevant choice of endpoints … the outlook is far from promising. The M&S approach should be integrative, from the molecular level to the clinical and population outcomes.

Vaccines 105

Vaccines Clinical Pharmacology Immunity Immunization 105

Express Pharma

JULY 3, 2023

How is the industry’s approach to drug development transforming? How is Waters aiding advancements in drug development? A central aim in drug development is to create new molecular entities into commercially viable drugs useful in managing diseases. What are the imperatives that led to this change?

Biosimilars 95

Biosimilars Drug Development Generic Medicine Diabetes 95

Express Pharma

APRIL 4, 2024

True enough, the use of liposomes and LNPs as carriers for highly specialised drug and biologic payloads, notably mRNA therapies, has experienced remarkable growth—notably, the initial SARS-CoV-2 vaccines authorised for use employed LNPs as delivery mechanisms for mRNA payloads. So, in that sense, both are effective in drug delivery.

Vaccines 98

Vaccines Compounding Immunity Immunization 98

pharmaphorum

SEPTEMBER 2, 2021

Anna Biosciences’ Dr Anthony Rullo discusses the drug development company’s immunotherapy platform. Syntem’s recently disclosed proprietary small molecule ‘covalent immune recruiting’ (CIR) technology that can enhance recognition of various pathologies by the host immune system.

Immunity 52

Immunity Immunization Vaccines Drug Development 52

pharmaphorum

JUNE 24, 2022

The initiative will focus on vaccines and medicines for diseases like malaria, tuberculosis, HIV and neglected tropical diseases (NTDs), which according to the drugmaker account for 60% of the disease burden in poorer regions of the world, as well as antimicrobial resistance. GSK will invest around £1 billion ($1.2

Vaccines 59

Vaccines Immunity Immunization Drug Development 59

Pharmaceutical Technology

JUNE 5, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Immunization 52

Immunization Immunity Vaccines Drug Development 52

pharmaphorum

DECEMBER 10, 2020

In the last few years it has been progressively adding to its capabilities, for example buying oncolytic virus specialist ViraTherapeutics in 2018 and cancer vaccine player AMAL Therapeutic s last year. Trodelvy is directed against Trop2, while NBE-002 targets ROR1, which along with TNBC is also seen in lung adenocarcinomas.

Vaccines 59

Vaccines Immunity Immunization Drug Development 59

Pharmaceutical Technology

JUNE 8, 2023

These solutions will help drug developers address the challenges of regulatory compliance, production scalability, quality assurance and cost-effectiveness. The new CGTs treat a broad range of indications including rare diseases, immune disorders and blood cancers.

Vaccines 52

Vaccines Drug Development Immunity Immunization 52

European Pharmaceutical Review

MARCH 4, 2024

These biopharmaceuticals encompass a range of products including vaccines, recombinant therapeutic proteins, tissues, cells and gene therapies – all sourced from living organisms. 1 However, the entry of biologics into the pharmaceutical market is not without unique challenges, particularly when compared to small molecule drugs.

Vaccines 98

Vaccines Immunity Immunization Compounding 98

Pharmaceutical Technology

FEBRUARY 14, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Diabetes 40

Diabetes Immunity Immunization Vaccines 40

European Pharmaceutical Review

FEBRUARY 13, 2025

As drug developers consider oligos potential, they often explore innovations in chemical modifications and delivery systems to ensure these therapies reach their full potential. Regulatory agencies recommend a tiered approach to assessing potential immune responses.

Compounding 52

Compounding Immunity Immunization Drug Development 52

Express Pharma

MAY 10, 2023

However, this philosophy isn’t just relegated to guiding the practices of medical professionals and drug developers. It extends all the way down to the healthcare sector’s expectations for every component, instrument, and process orbiting the development and manufacture of medicine—especially parenteral drugs.

Packaging 97

Packaging Dosage Labelling Immunity 97

Pharmaceutical Technology

AUGUST 26, 2008

We are now one of the ten largest biopharma companies in the world with a rich armoury of new technology, comprising a full suite of technologies, small molecules, antibodies and vaccines to create new human medicines.” The DEEP study results, along with data from further analyses, are under review by a potential licensing partner.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Vaccines Drug Development 40

European Pharmaceutical Review

OCTOBER 3, 2024

What are the main trends or recent advances in oral small molecule drug development? Daniel Vitt (DV): A current trend in oral small molecule drug development is a shift towards creating more selective and patient-friendly drugs.

Immunity 52

Immunity Immunization Drug Development Diabetes 52

European Pharmaceutical Review

JUNE 28, 2024

The post <em>European Pharmaceutical Review </em> Issue 3 2024 appeared first on European Pharmaceutical Review.

Research Laboratories 52

Research Laboratories Vaccines Drug Development Immunity 52

PharmaShots

JANUARY 31, 2023

Shots: Immutable capital demands and high-spending drug development plans are the most common drivers in encouraging fully-fledged private healthcare companies to go public. With an aim to develop a VLP-based vaccine candidate, Frazier and Takeda Pharmaceuticals underwent a collaboration to form Hillevax. of Shares: 1.3M

Vaccines 40

Vaccines Immunity Immunization Diabetes 40

PharmaShots

MARCH 14, 2023

The article focuses on challenges faced in drug development, government incentive programs, grants, and various therapies used to diagnose or treat rare diseases. How challenging is the drug development plan Drug development plans for rare diseases can be circuitous, resulting in fewer participation from companies.

Drug Development 40

Drug Development Immunity Immunization Compounding 40